Acute Myelogenous Leukemia Clinical Trials

279 clinical trials for Acute Myelogenous Leukemia across international registries, including 27 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Biology Studies of Hematologic Cancers — RECRUITING
• A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) — RECRUITING
• Allo HSCT Using RIC and PTCy for Hematological Diseases — RECRUITING · PHASE2
• Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution — RECRUITING
• Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT — RECRUITING · PHASE1
• Cord Blood Transplantation in Children and Young Adults With Blood Cancer — RECRUITING · PHASE2
• ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies — RECRUITING · PHASE1
• The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen — RECRUITING
• A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) — RECRUITING · PHASE1
• Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood — RECRUITING · PHASE2
• Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring — RECRUITING
• HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy — RECRUITING · PHASE2
• Cord Blood Transplant in Adults With Blood Cancers — RECRUITING · PHASE2
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — RECRUITING · PHASE2
• A PHASE 1/2 FIRST IN HUMAN STUDY OF THE MENIN-MLL (KMT2A) INHIBITOR KO 539 IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF ENTOSPLETINIB IN COMBINATION WITH INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY IN ADULTS WITH NEWLY DIAGNOSED NUCLEOPHOSMIN 1-MUTATED ACUTE MYELOID LEUKEMIA — RECRUITING · PHASE3
• Register AML-BFM 2017 for the registration of acute myelogenous leukemia in children and adolescents — RECRUITING
• A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA — RECRUITING · PHASE3
• A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG-221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION. — RECRUITING · PHASE3
• PHASE I STUDY OF AUTOLOGOUS ACUTE MYELOGENOUS LEUKEMIA (AML) CELLS CONTAINING LENTIVIRUS ENGINEERING EXPRESSION OF IL-12 — RECRUITING · PHASE1
• RISK-STRATIFIED THERAPY FOR ACUTE MYELOID LEUKEMIA IN DOWN SYNDROME — RECRUITING
• RANDOMIZED PHASE II STUDY TO ASSESS THE ROLE OF NIVOLUMAB AS SINGLE AGENT TO ELIMINATE MINIMAL RESIDUAL DISEASE AND MAINTAIN REMISSION IN ACUTE MYELOGENOUS LEUKEMIA (AML) PATIENTS AFTER CHEMOTHERAPY — RECRUITING · PHASE2
• A PHASE 1B/2 STUDY OF ENTOSPLETINIB (GS-9973) MONOTHERAPY AND IN COMBINATION WITH CHEMOTHERAPY IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA (AML) — RECRUITING · PHASE1
• AN OPEN-LABEL, PHASE 1B/2 STUDY INVESTIGATING RECOMMENDED PHASE 2 DOSE, SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF TAK-659 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) — RECRUITING · PHASE2
• A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF EPZ-5676 IN THE TREATMENT OF PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY LEUKEMIAS BEARING A REARRANGEMENT OF THE MLL GENE — RECRUITING · PHASE1
• A PHASE II, RANDOMIZED, COMPARATIVE TRIAL OF STANDARD OF CARE, WITH OR WITHOUT MIDOSTAURIN TO PREVENT RELAPSE FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA — RECRUITING · PHASE2
• A RANDOMIZED, BLINDED, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE ORAL THROMBOPOIETIN RECEPTOR AGONIST, ELTROMBOPAG, ADMINISTERED TO SUBJECTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) RECEIVING INDUCTION CHEMOTHERAPY — RECRUITING
• Testing eltrombopag in patients with acute myelogenous leukemia (AML) who receive chemotherapy with daunorubicin plus cytarabine — COMPLETED · PHASE2
• An early phase study which aims to find a dose, asses safety and tolerability of AKN-028 in Patients with Acute Myelogenous Leukemia (AML) — TERMINATED · PHASE2
• Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission — COMPLETED · PHASE2
• Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation — COMPLETED · PHASE1
• Dendritic Cell/AML Fusion Cell Vaccine Following Allogeneic Transplantation in AML Patients — ACTIVE_NOT_RECRUITING · PHASE1
• Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome — TERMINATED · PHASE1
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation — TERMINATED · PHASE3
• Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) — SUSPENDED · PHASE1
• HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide — ACTIVE_NOT_RECRUITING · PHASE2
• Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS — COMPLETED · PHASE3
• LILRB4 STAR-T Cell Therapy for Monocytic Leukemia — COMPLETED · NA
• DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission — ACTIVE_NOT_RECRUITING · PHASE2
• Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine — COMPLETED · PHASE1
• Resiliency in Older Adults Undergoing Bone Marrow Transplant — COMPLETED
• Epigenetic Reprogramming in Relapse/Refractory AML — COMPLETED · PHASE1
• Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML — NOT_YET_RECRUITING · PHASE2
• Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell — COMPLETED · PHASE1
• HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide — COMPLETED · PHASE2
• Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) — COMPLETED · PHASE1
• Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives — TERMINATED · PHASE2
• MCLA-117 in Acute Myelogenous Leukemia — TERMINATED · PHASE1
• Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation — COMPLETED · PHASE1

Refine this search